# reload+after+2024-01-21 00:47:51.013262
address1§2533 South Coast Highway 101
address2§Suite 210
city§Cardiff-by-the-Sea
state§CA
zip§92007
country§United States
phone§858 400 8470
website§https://www.viracta.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company's development pipeline also includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor; and VRx-510, a preclinical-stage PDK-1 inhibitor. The company was formerly known as Sunesis Pharmaceuticals, Inc. and changed its name to Viracta Therapeutics, Inc. in February 2021. Viracta Therapeutics, Inc. was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea, California.
fullTimeEmployees§41
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Mark Andrew Rothera', 'age': 60, 'title': 'CEO, President & Director', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 365032, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Daniel R. Chevallard CPA', 'age': 43, 'title': 'CFO, COO, Treasurer & Secretary', 'yearBorn': 1980, 'fiscalYear': 2022, 'totalPay': 647909, 'exercisedValue': 0, 'unexercisedValue': 37032}, {'maxAge': 1, 'name': 'Dr. Susan  Perrine M.D.', 'title': 'Scientific Founder and Consultant', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Ronald J. Berenson M.D.', 'age': 71, 'title': 'Co-Founder and Consultant', 'yearBorn': 1952, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. George  Hillman', 'title': 'Co-Founder', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Thalia  Papayannopoulou M.D.', 'title': 'Co-Founder', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Robert M. Williams Ph.D.', 'age': 68, 'title': 'Co-Founder', 'yearBorn': 1955, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Douglas V. Faller M.D., Ph.D.', 'title': 'Scientific Founder & Chairman of Scientific Advisory Board', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Ayman  El-Guindy', 'title': 'Chief Scientific Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Stewart M. Brown', 'title': 'Senior VP of Legal Affairs & General Counsel', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.066
currency§USD
dateShortInterest§1702598400
forwardEps§-1.26
pegRatio§0.0
exchange§NMS
quoteType§EQUITY
shortName§Viracta Therapeutics, Inc.
longName§Viracta Therapeutics, Inc.
firstTradeDateEpochUtc§1127827800
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§ed5f69f9-939f-3d89-84c4-600b43f665a9
gmtOffSetMilliseconds§-18000000
targetHighPrice§13.0
targetLowPrice§5.0
targetMeanPrice§8.5
targetMedianPrice§8.0
recommendationMean§1.5
recommendationKey§strong_buy
numberOfAnalystOpinions§4
quickRatio§1.741
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
